Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Profit After Tax (2017 - 2025)

Historic Profit After Tax for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Profit After Tax fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7312.89%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Profit After Tax of -$39.3 million as of Q3 2025, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Profit After Tax ranged from a high of $207.3 million in Q1 2024 and a low of -$41.0 million during Q2 2022
  • Moreover, its 5-year median value for Profit After Tax was -$33.2 million (2024), whereas its average is -$7.5 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 33545.02% in 2021, then skyrocketed by 71479.61% in 2024.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Profit After Tax stood at -$36.9 million in 2021, then grew by 7.35% to -$34.2 million in 2022, then surged by 179.94% to $27.3 million in 2023, then surged by 381.7% to $131.7 million in 2024, then crashed by 129.88% to -$39.3 million in 2025.
  • Its last three reported values are -$39.3 million in Q3 2025, -$34.8 million for Q2 2025, and -$11.7 million during Q1 2025.